Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRKAd5 HIV-1 Trigene + MRKAd6 HIV-1 Trigene
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination **HIV-1 vaccine investigational product** consisting of two replication-incompetent recombinant adenovirus vectors: MRKAd5 HIV-1 Trigene and MRKAd6 HIV-1 Trigene. Each vector expresses three near-consensus clade B HIV-1 genes—*gag*, *pol*, and *nef*. These genes are encoded within a transgene cassette under the control of viral promoters and polyadenylation signals, designed to elicit cell-mediated immune responses. The combination vaccine aims to induce T-cell immunity against multiple HIV-1 antigens, using vectors based on adenovirus serotypes 5 (Ad5) and 6 (Ad6) to address pre-existing vector immunity in different populations. Developed and tested in phase 1 clinical trials for its safety and immunogenicity, it has not demonstrated efficacy in preventing HIV-1 infection and has not advanced to regulatory approval[2][3].
- Other names
- MRKAd5+6 HIV-1 trigene vaccineMRKAd5/6 HIV-1 trigene vaccine
02
Targets
Gag (HIV-1 Gag polyprotein)HIV-1 Pol polyproteinNef (HIV-1 Nef)
Beyond the preview
Go deeper on MRKAd5 HIV-1 Trigene + MRKAd6 HIV-1 Trigene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRKAd5 HIV-1 Trigene + MRKAd6 HIV-1 Trigene.